The results of this small pilot study are preliminary, but we hope will stimulate larger studies to evaluate the role of ER-β isoforms as potential treatment targets in PAC, taking into consideration the levels of expression of each isoform in the target tumor, patient age, gender, use of exogenous steroidal hormones, and the pancreatic cancer subtypes. This evidence concerns the gene ESR2 and neoplasm.